{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:19:42Z","timestamp":1785410382785,"version":"3.56.0"},"reference-count":57,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T00:00:00Z","timestamp":1784332800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003042","name":"Else Kr\u00f6ner-Fresenius-Stiftung","doi-asserted-by":"crossref","award":["2020_EKPK.20"],"award-info":[{"award-number":["2020_EKPK.20"]}],"id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"crossref"}]},{"award":["2020_EKPK.20"],"award-info":[{"award-number":["2020_EKPK.20"]}],"id":[{"id":"https:\/\/ror.org\/03zcxha54","id-type":"ROR","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005677","name":"Deutsche Jos\u00e9 Carreras Leuk\u00e4mie-Stiftung","doi-asserted-by":"publisher","award":["16 R\/2021"],"award-info":[{"award-number":["16 R\/2021"]}],"id":[{"id":"10.13039\/501100005677","id-type":"DOI","asserted-by":"publisher"}]},{"award":["16 R\/2021"],"award-info":[{"award-number":["16 R\/2021"]}],"id":[{"id":"https:\/\/ror.org\/00826gz80","id-type":"ROR","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["70114189"],"award-info":[{"award-number":["70114189"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"award":["70114189"],"award-info":[{"award-number":["70114189"]}],"id":[{"id":"https:\/\/ror.org\/01wxdd722","id-type":"ROR","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["101136502"],"award-info":[{"award-number":["101136502"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["101104421"],"award-info":[{"award-number":["101104421"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"award":["101136502"],"award-info":[{"award-number":["101136502"]}],"id":[{"id":"https:\/\/ror.org\/019w4f821","id-type":"ROR","asserted-by":"publisher"}]},{"award":["101104421"],"award-info":[{"award-number":["101104421"]}],"id":[{"id":"https:\/\/ror.org\/019w4f821","id-type":"ROR","asserted-by":"publisher"}]},{"name":"Verein f\u00fcr krebskranke Kinder Hannover e.V."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: Spectral flow cytometry enables the single-tube integration of all markers required for the assessment of measurable residual disease (MRD) in AML. The routine clinical use of spectral flow cytometry is challenged by the need for adequate single-stained unmixing controls. To pave the way for the clinical implementation of spectral flow cytometry, we opted to develop a multifunctional AML MRD panel, whose unmixing routine solely depends on ubiquitously available peripheral blood leukocytes (PBLs). Methods: We reconfigured our previously developed 19-color single-tube spectral MRD assay to incorporate viability, hemodilution, and leukemic stem cell (LSC) markers. In parallel, primitive markers were reassigned to non-tandem fluorochromes, resulting in a finalized 22-color panel. These fluorochromes were additionally leveraged as CD14 surrogate controls, whereas all other markers retained their dedicated fluorochromes for unmixing based on single-stained PBLs. Results: PBL-based controls enabled accurate spectral unmixing and reproducible assessment of CD16-based hemodilution and cell viability in spike-in experiments. Linear leukemia-associated immunophenotype (LAIP) detection, sensitivity, as well as intra- and inter-assay precision within predefined acceptance criteria were demonstrated in KG-1 dilution experiments using normal bone marrow (nBM). Furthermore, the 22-color assay resolved LAIPs and LSCs in patient samples with strong concordance to the 5-tube reference assay and revealed aberrant marker combinations that could not be assessed using the multi-tube design. Conclusions: This single-tube 22-color spectral flow cytometry assay may support a more clinically applicable and potentially standardizable approach to AML MRD diagnostics through a universal PBL-based unmixing strategy.<\/jats:p>","DOI":"10.3390\/cancers18142323","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T02:32:08Z","timestamp":1784514728000},"page":"2323","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Clinically Applicable Unmixing Approach for Spectral MRD Detection in AML"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-5037-8020","authenticated-orcid":false,"given":"Julian-Philipp","family":"Waclawski","sequence":"first","affiliation":[{"name":"Department of Hematology, Hemostasis, Oncology, and Cell Therapy, Hannover Medical School, 30625 Hannover, Germany"},{"name":"Department of Pediatric Hematology and Oncology, Hannover Medical School, 30625 Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabell","family":"Arnhardt","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hemostasis, Oncology, and Cell Therapy, Hannover Medical School, 30625 Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5363-1354","authenticated-orcid":false,"given":"Hendrik","family":"Fokken","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hemostasis, Oncology, and Cell Therapy, Hannover Medical School, 30625 Hannover, Germany"},{"name":"Department of Pediatric Hematology and Oncology, Hannover Medical School, 30625 Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Kattre","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hemostasis, Oncology, and Cell Therapy, Hannover Medical School, 30625 Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daphne","family":"den Hartog","sequence":"additional","affiliation":[{"name":"Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, 1081 HV Amsterdam, The Netherlands"},{"name":"Cancer Center Amsterdam, Imaging and Biomarkers, 1081 HV Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander N.","family":"Snel","sequence":"additional","affiliation":[{"name":"Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, 1081 HV Amsterdam, The Netherlands"},{"name":"Cancer Center Amsterdam, Imaging and Biomarkers, 1081 HV Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angele","family":"Kelder","sequence":"additional","affiliation":[{"name":"Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, 1081 HV Amsterdam, The Netherlands"},{"name":"Cancer Center Amsterdam, Imaging and Biomarkers, 1081 HV Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9097-5179","authenticated-orcid":false,"given":"Jessica","family":"Herbst","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology and Oncology, Hannover Medical School, 30625 Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin G.","family":"Sauer","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology and Oncology, Hannover Medical School, 30625 Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Stadler","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hemostasis, Oncology, and Cell Therapy, Hannover Medical School, 30625 Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Heuser","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hemostasis, Oncology, and Cell Therapy, Hannover Medical School, 30625 Hannover, Germany"},{"name":"Department of Internal Medicine IV, University Hospital Halle (Saale), Martin-Luther-University Halle-Wittenberg, 06120 Halle, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5983-6193","authenticated-orcid":false,"given":"Costa","family":"Bachas","sequence":"additional","affiliation":[{"name":"Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, 1081 HV Amsterdam, The Netherlands"},{"name":"Cancer Center Amsterdam, Imaging and Biomarkers, 1081 HV Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Schwarzer","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hemostasis, Oncology, and Cell Therapy, Hannover Medical School, 30625 Hannover, Germany"},{"name":"Department of Internal Medicine C: Hematology, Oncology and Stem Cell Transplantation, University Medicine Greifswald, 17475 Greifswald, Germany"},{"name":"Comprehensive Cancer Center Mecklenburg-Vorpommern, University Medicine Greifswald, 17489 Greifswald, Germany"},{"name":"Institute of Experimental Hematology, Hannover Medical School, 30625 Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8259-3150","authenticated-orcid":false,"given":"Tobias","family":"Maetzig","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology and Oncology, Hannover Medical School, 30625 Hannover, Germany"},{"name":"Institute of Experimental Hematology, Hannover Medical School, 30625 Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1080\/17474086.2021.1886920","article-title":"The Important Role of Intensive Induction Chemotherapy in the Treatment of Acute Myeloid Leukemia","volume":"14","author":"Lin","year":"2021","journal-title":"Expert Rev. Hematol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1002\/ajh.27625","article-title":"Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk-Stratification, and Management","volume":"100","author":"Shimony","year":"2025","journal-title":"Am. J. Hematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s11899-017-0420-z","article-title":"The Prognostic Significance of Measurable (\u201cMinimal\u201d) Residual Disease in Acute Myeloid Leukemia","volume":"12","author":"Buccisano","year":"2017","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1001\/jamaoncol.2020.4600","article-title":"Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis","volume":"6","author":"Short","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 Update on MRD in Acute Myeloid Leukemia: A Consensus Document from the European LeukemiaNet MRD Working Party","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1002\/cpcy.73","article-title":"Acute Myeloid Leukemia Minimal Residual Disease Detection: The Difference from Normal Approach","volume":"93","author":"Wood","year":"2020","journal-title":"Curr. Protoc. Cytom."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e66","DOI":"10.1002\/cpcy.66","article-title":"Immunophenotypic Detection of Measurable Residual (Stem Cell) Disease Using LAIP Approach in Acute Myeloid Leukemia","volume":"91","author":"Zeijlemaker","year":"2019","journal-title":"Curr. Protoc. Cytom."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/j.1751-553X.2012.01416.x","article-title":"Minimal Residual Disease Detection Defined as the Malignant Fraction of the Total Primitive Stem Cell Compartment Offers Additional Prognostic Information in Acute Myeloid Leukaemia","volume":"34","author":"Terwijn","year":"2012","journal-title":"Int. J. Lab. Hematol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Hanekamp, D., Tettero, J.M., Ossenkoppele, G.J., Kelder, A., Cloos, J., and Schuurhuis, G.J. (2021). AML\/Normal Progenitor Balance Instead of Total Tumor Load (MRD) Accounts for Prognostic Impact of Flowcytometric Residual Disease in AML. Cancers, 13.","DOI":"10.3390\/cancers13112597"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1182\/blood.2021014604","article-title":"An LSC-Based MRD Assay to Complement the Traditional MFC Method for Prediction of AML Relapse: A Prospective Study","volume":"140","author":"Li","year":"2022","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/leu.2015.252","article-title":"A Simple One-Tube Assay for Immunophenotypical Quantification of Leukemic Stem Cells in Acute Myeloid Leukemia","volume":"30","author":"Zeijlemaker","year":"2016","journal-title":"Leukemia"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/s41375-018-0326-3","article-title":"CD34+CD38\u2212 Leukemic Stem Cell Frequency to Predict Outcome in Acute Myeloid Leukemia","volume":"33","author":"Zeijlemaker","year":"2019","journal-title":"Leukemia"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/bjh.13941","article-title":"CD 45 RA, a Specific Marker for Leukaemia Stem Cell Sub-populations in Acute Myeloid Leukaemia","volume":"173","author":"Kersten","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41375-024-02148-3","article-title":"Peri-Transplant Flow-MRD Assessment of Cells with Leukemic Stem Cells (LSC) Associated Phenotype in AML Patients Undergoing Allogeneic Stem Cell Transplantation in CR","volume":"38","author":"Klyuchnikov","year":"2024","journal-title":"Leukemia"},{"key":"ref_15","first-page":"56386","article-title":"Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia","volume":"133","author":"Cloos","year":"2018","journal-title":"J. Vis. Exp."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/cyto.a.24667","article-title":"Development of a 27-color Panel for the Detection of Measurable Residual Disease in Patients Diagnosed with Acute Myeloid Leukemia","volume":"101","author":"Soh","year":"2022","journal-title":"Cytom. Part A"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/cyto.a.24811","article-title":"A 19-color Single-tube Full Spectrum Flow Cytometry Assay for the Detection of Measurable Residual Disease in Acute Myeloid Leukemia","volume":"105","author":"Fokken","year":"2024","journal-title":"Cytom. Part A"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"20230745","DOI":"10.1515\/med-2023-0745","article-title":"Twenty-Four-Color Full Spectrum Flow Cytometry Panel for Minimal Residual Disease Detection in Acute Myeloid Leukemia","volume":"18","author":"Chen","year":"2023","journal-title":"Open Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/cyto.a.24958","article-title":"Development of a 29-Color Single-Tube Full Spectrum Flow Cytometry Assay for the Detection of Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia","volume":"107","author":"Zhang","year":"2025","journal-title":"Cytom. Part A"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1002\/cyto.a.24566","article-title":"The Evolution of Spectral Flow Cytometry","volume":"101","author":"Nolan","year":"2022","journal-title":"Cytom. Part A"},{"key":"ref_21","first-page":"1.27.1","article-title":"Spectral Flow Cytometry","volume":"63","author":"Nolan","year":"2013","journal-title":"Curr. Protoc. Cytom."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1111\/imcb.12456","article-title":"Making the Most of High-dimensional Cytometry Data","volume":"99","author":"Mitchell","year":"2021","journal-title":"Immunol. Cell Biol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Den Braanker, H., Bongenaar, M., and Lubberts, E. (2021). How to Prepare Spectral Flow Cytometry Datasets for High Dimensional Data Analysis: A Practical Workflow. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.768113"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1002\/cyto.a.24836","article-title":"Fluorochrome-dependent Specific Changes in Spectral Profiles Using Different Compensation Beads or Primary Cells in Full Spectrum Cytometry","volume":"105","author":"Shevchenko","year":"2024","journal-title":"Cytom. Part A"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/s41592-023-02042-3","article-title":"A Practitioner\u2019s View of Spectral Flow Cytometry","volume":"21","author":"Sharma","year":"2024","journal-title":"Nat. Methods"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"819","DOI":"10.4049\/immunohorizons.2300066","article-title":"Side-by-Side Comparison of Compensation Beads Used in Polychromatic Flow Cytometry","volume":"7","author":"Bhowmick","year":"2023","journal-title":"ImmunoHorizons"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1002\/cyto.a.24213","article-title":"OMIP-069: Forty-Color Full Spectrum Flow Cytometry Panel for Deep Immunophenotyping of Major Cell Subsets in Human Peripheral Blood","volume":"97","author":"Park","year":"2020","journal-title":"Cytom. Part A"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/cyto.a.24708","article-title":"iCoreDrop: A Robust Immune Monitoring Spectral Cytometry Assay with Six Open Channels for Biomarker Flexibility","volume":"103","author":"Jensen","year":"2023","journal-title":"Cytom. Part A"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/cyto.b.20429","article-title":"Normalization of Bone Marrow Aspirates for Hemodilution in Flow Cytometric Analyses","volume":"76","author":"Loken","year":"2009","journal-title":"Cytom. Part B Clin. Cytom."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/cyto.a.24501","article-title":"PeacoQC: Peak-based Selection of High Quality Cytometry Data","volume":"101","author":"Emmaneel","year":"2022","journal-title":"Cytom. Part A"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"861","DOI":"10.21105\/joss.00861","article-title":"UMAP: Uniform Manifold Approximation and Projection","volume":"3","author":"McInnes","year":"2018","journal-title":"J. Open Source Softw."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1002\/cyto.a.22625","article-title":"FlowSOM: Using Self-organizing Maps for Visualization and Interpretation of Cytometry Data","volume":"87","author":"Callebaut","year":"2015","journal-title":"Cytom. Part A"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jim.2016.12.006","article-title":"A Simple Flow-Cytometry Method to Evaluate Peripheral Blood Contamination of Bone Marrow Aspirates","volume":"442","author":"Delgado","year":"2017","journal-title":"J. Immunol. Methods"},{"key":"ref_34","first-page":"1038","article-title":"A Novel Method to Assess Bone Marrow Purity Is Useful in Determining Blast Percentage by Flow Cytometry in Acute Myeloid Leukemia and Myelodysplasia","volume":"2","author":"Aldawood","year":"2015","journal-title":"Ann. Hematol. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","article-title":"Minimal\/Measurable Residual Disease in AML: A Consensus Document from the European LeukemiaNet MRD Working Party","volume":"131","author":"Schuurhuis","year":"2018","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/cyto.a.24686","article-title":"Identification of Critical Hemodilution by Artificial Intelligence in Bone Marrow Assessed for Minimal Residual Disease Analysis in Acute Myeloid Leukemia: The Cinderella Method","volume":"103","author":"Hoffmann","year":"2023","journal-title":"Cytom. Part A"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1038\/leu.2017.29","article-title":"Next Generation Flow for Highly Sensitive and Standardized Detection of Minimal Residual Disease in Multiple Myeloma","volume":"31","author":"Paiva","year":"2017","journal-title":"Leukemia"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"472","DOI":"10.3324\/haematol.2014.112755","article-title":"Multicentric Study Underlining the Interest of Adding CD5, CD7 and CD56 Expression Assessment to the Flow Cytometric Ogata Score in Myelodysplastic Syndromes and Myelodysplastic\/Myeloproliferative Neoplasms","volume":"100","author":"Bardet","year":"2015","journal-title":"Haematologica"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"on behalf of the EuroFlow Consortium (EU-FP6, LSHB-CT-2006-018708), Van Dongen, J.J.M., Lhermitte, L., B\u00f6ttcher, S., Almeida, J., Van Der Velden, V.H.J., Flores-Montero, J., Rawstron, A., Asnafi, V., and L\u00e9crevisse, Q. (2012). EuroFlow Antibody Panels for Standardized N-Dimensional Flow Cytometric Immunophenotyping of Normal, Reactive and Malignant Leukocytes. Leukemia, 26, 1908\u20131975.","DOI":"10.1038\/leu.2012.120"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/cyto.b.22144","article-title":"Analytical Assay Validation for Acute Myeloid Leukemia Measurable Residual Disease Assessment by Multiparametric Flow Cytometry","volume":"104","author":"Tettero","year":"2023","journal-title":"Cytom. Part B Clin. Cytom."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e868","DOI":"10.1002\/cpz1.868","article-title":"Flow Cytometry Method Validation Protocols","volume":"3","author":"Selliah","year":"2023","journal-title":"Curr. Protoc."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41375-024-02158-1","article-title":"Impact of Hemodilution on Flow Cytometry Based Measurable Residual Disease Assessment in Acute Myeloid Leukemia","volume":"38","author":"Tettero","year":"2024","journal-title":"Leukemia"},{"key":"ref_43","first-page":"S49","article-title":"Limit of Blank, Limit of Detection and Limit of Quantitation","volume":"29","author":"Armbruster","year":"2008","journal-title":"Clin. Biochem. Rev."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Van Dongen, J.J.M., Van Der Burg, M., Kalina, T., Perez-Andres, M., Mejstrikova, E., Vlkova, M., Lopez-Granados, E., Wentink, M., Kienzler, A.-K., and Philipp\u00e9, J. (2019). EuroFlow-Based Flowcytometric Diagnostic Screening and Classification of Primary Immunodeficiencies of the Lymphoid System. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.01271"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/cyto.b.21108","article-title":"Validation of Cell-based Fluorescence Assays: Practice Guidelines from the ICSH and ICCS\u2014Part V\u2014Assay Performance Criteria","volume":"84","author":"Wood","year":"2013","journal-title":"Cytom. Part B Clin. Cytom."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1038\/sj.leu.2402245","article-title":"Functional Characterization of Minimal Residual Disease for P-Glycoprotein and Multidrug Resistance Protein Activity in Acute Myeloid Leukemia","volume":"15","author":"Pater","year":"2001","journal-title":"Leukemia"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/bjh.15711","article-title":"Revisiting CLEC 12A as Leukaemic Stem Cell Marker in AML: Highlighting the Necessity of Precision Diagnostics in Patients Eligible for Targeted Therapy","volume":"184","author":"Bill","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/cas.16431","article-title":"TIM-3 Marks Measurable Residual Leukemic Stem Cells Responsible for Relapse after Allogeneic Stem Cell Transplantation","volume":"116","author":"Sakoda","year":"2025","journal-title":"Cancer Sci."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/s41590-024-01782-4","article-title":"An Immunophenotype-Coupled Transcriptomic Atlas of Human Hematopoietic Progenitors","volume":"25","author":"Zhang","year":"2024","journal-title":"Nat. Immunol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s43586-022-00156-0","article-title":"Spectral Cytometry on Highly Autofluorescent Samples","volume":"2","author":"Lokwani","year":"2022","journal-title":"Nat. Rev. Methods Primer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/cyto.a.22251","article-title":"Quantifying Spillover Spreading for Comparing Instrument Performance and Aiding in Multicolor Panel Design","volume":"83A","author":"Nguyen","year":"2013","journal-title":"Cytom. Part A"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1002\/cyto.a.24166","article-title":"Multispectral Flow Cytometry: Unaddressed Issues and Recommendations for Improvement","volume":"97","author":"Parks","year":"2020","journal-title":"Cytom. Part A"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1038\/s41467-021-23126-8","article-title":"AutoSpill Is a Principled Framework That Simplifies the Analysis of Multichromatic Flow Cytometry Data","volume":"12","author":"Roca","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Terwijn, M., Zeijlemaker, W., Kelder, A., Rutten, A.P., Snel, A.N., Scholten, W.J., Pabst, T., Verhoef, G., L\u00f6wenberg, B., and Zweegman, S. (2014). Leukemic Stem Cell Frequency: A Strong Biomarker for Clinical Outcome in Acute Myeloid Leukemia. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0107587"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/cyto.a.70044","article-title":"Measurement and Prediction of Unmixing-Dependent Spreading Due to Collinearity in Spectral Flow Cytometry","volume":"109","author":"Mage","year":"2026","journal-title":"Cytom. Part A"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1002\/cpcy.70","article-title":"Panel Design and Optimization for High-Dimensional Immunophenotyping Assays Using Spectral Flow Cytometry","volume":"92","author":"Pellefigues","year":"2020","journal-title":"Curr. Protoc. Cytom."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.4155\/bio-2021-0201","article-title":"With Great Power Comes Great Responsibility: High-Dimensional Spectral Flow Cytometry to Support Clinical Trials","volume":"13","author":"McCausland","year":"2021","journal-title":"Bioanalysis"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/14\/2323\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T04:12:38Z","timestamp":1784520758000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/14\/2323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,18]]},"references-count":57,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["cancers18142323"],"URL":"https:\/\/doi.org\/10.3390\/cancers18142323","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,18]]}}}